With your own knowledge and the help of the following document:

Document 1 (Title: Pharmacotherapy of Entamoeba histolytica Infections): Amebiasis management requires targeted pharmacological approaches addressing both intestinal and tissue infections through agents with distinctive spectrum and distribution characteristics. Therapeutic approaches typically distinguish between luminal agents effective against intestinal colonization versus tissue amebicides capable of treating invasive disease including hepatic abscesses. Nitroimidazole derivatives represent the cornerstone of tissue amebicide therapy due to their excellent distribution characteristics and direct amebicidal activity in hepatic and other extraintestinal sites. Metronidazole (FLAGYL®) demonstrates excellent tissue penetration and efficacy against invasive amebiasis, achieving therapeutic concentrations in hepatic abscess fluid and other invasive sites. Clinical studies document cure rates exceeding 90% for uncomplicated amebic liver abscess following appropriate metronidazole regimens. Similarly, secnidazole (FLAGENTYL®) provides effective treatment for tissue amebiasis with the advantage of single-dose administration due to its extended half-life compared to other nitroimidazoles. This pharmacokinetic advantage facilitates improved adherence in resource-limited settings while maintaining comparable clinical efficacy. Ornidazole (TIBÉRAL®) represents another effective tissue amebicide within the nitroimidazole class, demonstrating excellent penetration into hepatic tissue and abscess cavities with similar efficacy profiles to other class members. These agents contrast with medications primarily effective against intestinal luminal infection, including paramomycin and diloxanide furoate, which demonstrate poor systemic absorption limiting their utility against tissue invasion. Similarly, antifungal agents including econazole (PEVARYL®) lack amebicidal activity despite activity against certain other parasites, while antihelminthic agents such as flubendazole (FLUVERMAL®) demonstrate no meaningful activity against protozoan pathogens including Entamoeba histolytica. These pharmacological distinctions inform appropriate agent selection for amebiasis, typically requiring nitroimidazole derivatives for tissue invasion followed by luminal agents to prevent recurrence.
Document 2 (Title: Exploring novel pyrazole nitroimidazole hybrids): “Trichomoniasis, a prevalent sexually transmitted infection (STI) caused by the protozoan Trichomonas vaginalis, has gained increased significance globally. Its relevance has grown in recent years due to its association with a heightened risk of acquiring and transmitting the human immunodeficiency virus (HIV) and other STIs. In addition, many publications have revealed a potential link between trichomoniasis and certain cancers. Metronidazole, a nitroimidazole compound developed over 50 years ago, remains the first choice drug for treatment. However, reports of genotoxicity and side effects underscore the necessity for new compounds to address this pressing global health concern. In this study, we synthesized ten pyrazole nitroimidazoles 1(a j) and 4 nitro 1 (hydroxyethyl) 1H imidazole 2, an analog of metronidazole, and assessed their trichomonacidal and cytotoxic effects. All compounds 1(a j) and 2 exhibited IC50 values ≤ 20 μM and ≤ 41 μM, after 24 h and 48 h, respectively. Compounds 1d (IC50 5.3 μM), 1e (IC50 4.8 μM), and 1i (IC50 5.2 μM) exhibited potencies equivalent to Metronidazole (IC50 4.9 μM), the reference drug, after 24 h. Notably, compound 1i showed high anti trichomonas activity after 24 h (IC50 5.2 μM) and 48 h (IC50 2.1 μM). Additionally, all compounds demonstrated either non cytotoxic to HeLa cells (CC50 > 100 μM) or low cytotoxicity (CC50 between 69 and 100 μM). These findings suggest that pyrazole nitroimidazole derivatives represent a promising heterocyclic system, serving as a potential lead for further optimization in trichomoniasis chemotherapy.
Document 3 (Title: Parasitology and Management of Enterobius vermicularis Infection): Enterobius vermicularis (pinworm) infection represents a common helminthic condition with distinctive clinical and epidemiological characteristics requiring accurate understanding for appropriate diagnosis and management. The parasitic lifecycle demonstrates several notable features influencing clinical presentation and treatment approaches. Following ingestion of infective eggs, larval development progresses relatively rapidly through the gastrointestinal tract, with mature female worms typically beginning egg deposition within 4-6 weeks of initial infection rather than extended 3-month maturation periods documented with certain other helminthic species. Egg deposition occurs primarily through nocturnal migration of female worms to the perianal region, creating the characteristic pruritus ani that often prompts medical attention. Pulmonary involvement including Löffler's syndrome (transient pulmonary infiltrates with eosinophilia) represents a potential manifestation of certain tissue-migrating helminthic infections but characteristically does not occur during pinworm infection due to its non-migratory lifecycle confined to the intestinal lumen. Hematological assessment typically reveals minimal abnormalities, though mild eosinophilia (5-15%) may occasionally develop in some cases, particularly with heavy parasite burdens or prolonged infection. Diagnostic approaches focus on detection of characteristic eggs through adhesive tape preparations rather than direct visualization of adult worms, which remain predominantly within the intestinal lumen rather than being evacuated through the oral route, distinguishing this infection from certain other parasitic conditions where adult worm passage may occur. Treatment typically involves benzimidazole compounds including mebendazole and albendazole, with flubendazole representing an alternative therapeutic option in some geographical regions. Comprehensive management includes treating household contacts and environmental measures addressing potential fomite transmission through bedding and clothing.

Answer the following list question.
Question: Select the medication(s) used as tissue amebicide(s):
Options:
1. Flubendazole (FLUVERMAL®)
2. Metronidazole (FLAGYL®)
3. Secnidazole (FLAGENTYL®)
4. Econazole (PEVARYL®)
5. Ornidazole (TIBÉRAL)

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ← if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.